Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03965039 · ClinicalTrials.gov registry record · NA
A Clinical Study to Assess the Effects of Various Dentifrice Technologies on Dentinal Hypersensitivity
A NA study of Dentin Hypersensitivity, sponsored by Procter and Gamble.
- Completed
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT03965039: Completed NA study of Dentin Hypersensitivity, sponsored by Procter and Gamble.
NCT03965039 is a NA study of Dentin Hypersensitivity that has completed, run by Procter and Gamble. The registered enrollment target is 120 participants, below the 358-participant average among 4 other Dentin Hypersensitivity trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03965039, a NA study of Dentin Hypersensitivity, has completed, sponsored by Procter and Gamble.
- COMPLETED
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate the efficacy (changes in dentinal hypersensitivity) and safety (oral soft tissue evaluation) after use of one of four dentifrices in subjects with pre-existing hypersensitivity over an 11-week period.
Primary Outcome
The Schiff Sensitivity Scale will be assessed for each test tooth via an evaporative air challenge. The examiner will record the Schiff Index score corresponding to the response to the air challenge. The Schiff Index Sensitivity scale is scored as follows- 0: tooth/subject did not respond to stimulus, 1: tooth/subject responds to stimulus, but does not request discontinuation of stimulus, 2: tooth/subject responds to stimulus and requests discontinuation or moves form stimulus, 3: tooth/subject
Conditions Studied
Interventions
- DEVICE Dipotassium oxalate toothpaste
- DRUG Stannous fluoride toothpaste
- DRUG Potassium nitrate toothpaste
- DRUG Sodium monofluorophosphate toothpaste
Study Locations (1)
Nevada
- Silverstone Research Group - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2019-07-08 |
| Est. Completion | 2019-10-03 |
| Phase | NA |
What the finished NCT03965039 record still lists
NCT03965039 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 358-participant average among 4 other Dentin Hypersensitivity trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Dentin Hypersensitivity appearing as the primary indexed condition, and to 4 interventions - of which Dipotassium oxalate toothpaste is the first listed.
NCT03965039 reports a single indexed study location in Nevada.
Frequently Asked Questions
What is clinical trial NCT03965039 about?
NCT03965039 is a clinical study titled "A Clinical Study to Assess the Effects of Various Dentifrice Technologies on Dentinal Hypersensitivity". The objective of this study is to evaluate the efficacy (changes in dentinal hypersensitivity) and safety (oral soft tissue evaluation) after use of one of four dentifrices in subjects with pre-existing hypersensitivity over an 11-week period.
What is the current status of trial NCT03965039?
This trial is currently completed. It is a NA study. The enrollment target is 120 participants. The study started on 2019-07-08. Estimated completion is 2019-10-03.
What conditions does trial NCT03965039 study?
This clinical trial studies the following conditions: Dentin Hypersensitivity.
What interventions are being tested in trial NCT03965039?
The interventions under investigation include: Dipotassium oxalate toothpaste (DEVICE), Stannous fluoride toothpaste (DRUG), Potassium nitrate toothpaste (DRUG), Sodium monofluorophosphate toothpaste (DRUG).
Who is sponsoring clinical trial NCT03965039?
This trial is sponsored by Procter and Gamble, which has 70 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03965039 being conducted?
This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dentin Hypersensitivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Tooth Whitening and Dentin Hypersensitivity Effectiveness of Two Experimental Toothpastes
RECRUITING · NA
-
A Comparison Study of Hypersensitivity Treatment
COMPLETED · NA
-
Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice
RECRUITING · Phase 3
-
A Study Evaluating Oral-Health-Related Quality of Life and Treatment Patterns Among Dentin Hypersensitivity Sufferers
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI